Scholarlink

Purpose <p>Bone marrow carcinomatosis (BMC) is a rare but clinically relevant manifestation of metastatic breast cancer (mBC), characterized by diffuse marrow infiltration and hematologic dysfunction. Evidence on epidemiology, clinical presentation, prognosis, and optimal treatment is limited. We performed a bicentric retrospective real-world analysis of patients diagnosed with BMC, representing the largest reported European cohort to date.</p> Methods <p>We retrospectively analyzed 37 patients diagnosed with BMC at two German university breast cancer centers between 2010 and 2023. Clinical characteristics, hematologic abnormalities, metastatic patterns, treatments, and overall survival (OS) were evaluated. Incidence estimates were calculated based on institutional breast cancer and mBC populations. A systematic literature review contextualized the findings.</p> Results <p>The estimated incidence of BMC was 2.6% among patients with mBC and 0.5% among all breast cancer cases. Most patients had HR-positive/HER2-negative disease (89%). Hematologic abnormalities were frequent, including anemia (84%), thrombocytopenia (76%), and pancytopenia (57%). Median OS after BMC diagnosis was 12 months (95% CI 6.0–38.0). Patients with bone-only metastases did not reach median OS, whereas those with additional metastatic sites had a median OS of 9 months (95% CI 5.0–12.0). Patients receiving endocrine therapy plus CDK4/6 inhibition showed numerically longer OS (34 months, 95% CI 5.0–NA) compared with chemotherapy alone (12 months, 95% CI 5.0–38.0).</p> Conclusions <p>BMC remains a rare but challenging complication of mBC. Endocrine-based targeted therapy may improve outcomes in selected HR-positive/HER2-negative patients. Larger multicenter studies are needed to optimize diagnosis and treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world insights into bone marrow carcinomatosis in metastatic breast cancer: a retrospective analysis from two large university breast cancer centers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月23日

查看全文
  • Nikolas Tauber,
  • Melissa Neubacher,
  • Niklas Amann,
  • Jan P. Cieslik,
  • Irene Esposito,
  • Franziska Fick,
  • Catharina Freier,
  • Verena Friebe,
  • Martina Helbig,
  • Franziska Hemptenmacher,
  • Lisbeth Hilmer,
  • Bernadette Jäger,
  • Kerstin Muras,
  • Anna E. M. Polkaehn,
  • Henriette Princk,
  • Eugen Ruckhäberle,
  • Maximilian Seidl,
  • Tanja Fehm,
  • Achim Rody,
  • Fabian Kohls,
  • Maggie Banys-Paluchowski,
  • Natalia Krawczyk

摘要

Purpose

Bone marrow carcinomatosis (BMC) is a rare but clinically relevant manifestation of metastatic breast cancer (mBC), characterized by diffuse marrow infiltration and hematologic dysfunction. Evidence on epidemiology, clinical presentation, prognosis, and optimal treatment is limited. We performed a bicentric retrospective real-world analysis of patients diagnosed with BMC, representing the largest reported European cohort to date.

Methods

We retrospectively analyzed 37 patients diagnosed with BMC at two German university breast cancer centers between 2010 and 2023. Clinical characteristics, hematologic abnormalities, metastatic patterns, treatments, and overall survival (OS) were evaluated. Incidence estimates were calculated based on institutional breast cancer and mBC populations. A systematic literature review contextualized the findings.

Results

The estimated incidence of BMC was 2.6% among patients with mBC and 0.5% among all breast cancer cases. Most patients had HR-positive/HER2-negative disease (89%). Hematologic abnormalities were frequent, including anemia (84%), thrombocytopenia (76%), and pancytopenia (57%). Median OS after BMC diagnosis was 12 months (95% CI 6.0–38.0). Patients with bone-only metastases did not reach median OS, whereas those with additional metastatic sites had a median OS of 9 months (95% CI 5.0–12.0). Patients receiving endocrine therapy plus CDK4/6 inhibition showed numerically longer OS (34 months, 95% CI 5.0–NA) compared with chemotherapy alone (12 months, 95% CI 5.0–38.0).

Conclusions

BMC remains a rare but challenging complication of mBC. Endocrine-based targeted therapy may improve outcomes in selected HR-positive/HER2-negative patients. Larger multicenter studies are needed to optimize diagnosis and treatment strategies.